23 May 2013
Keywords: Nanobiotix, NBTXR3, Soft tissue sarcoma
Article | 15 September 2011
Nanobiotix, an emerging French nanomedicine company focused on cancer therapy, says that its lead compound, NBTXR3, has received the formal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 September 2011
22 May 2013
© 2013 thepharmaletter.com